PGY-2 Oncology Resident The Ohio State University Columbus, Ohio, United States
Poster Abstract:
Background: Lymphodepleting chemotherapy with fludarabine and cyclophosphamide plays a pivotal role in enhancing the efficacy of CAR-T therapy and optimizing clinical outcomes. Fludarabine dosing based on body surface area results in highly variable pharmacokinetics. Given emerging evidence that fludarabine exposure is a predictor of efficacy and safety for some CAR-T products, it is vital to validate these data and establish an optimal level of fludarabine exposure prior to CAR-T.
Methods: This single-center retrospective chart review included adult patients with a lymphoma diagnosis who were treated with axicabtagene cilolucel or tisagenlecleucel at The Ohio State University Arther G James Cancer Hospital between October 2017 and October 2023. The primary outcome of interest was to compare event-free survival in patients who had optimal levels of fludarabine exposure compared to those who had low or high exposure. Fludarabine exposure was estimated by calculating a predicted area under the curve value using a population pharmacokinetic model. Secondary outcomes of interest included overall survival; best response achieved after CAR-T therapy; and incidence of cytokine release syndrome, immune effector cell-associated neurotoxicity, and early, delayed, and late cytopenias.
Results: Pending
Conclusions: Pending
References (must also be included in final poster): YESCARTA® (axicabtagene cilolucel) [package insert]. Santa Monica, CA: Kite Pharma, Inc.; 2022.
Salter AI, Pont MJ, Riddell SR. Chimeric antigen receptor-modified T cells: CD19 and the road beyond. Blood. 2018;131(24):2621-2629. doi:10.1182/blood-2018-01-785840
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20(1):31-42. doi:10.1016/S1470-2045(18)30864-7
Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91-103. doi:10.1016/S1470-2045(21)00591-X
Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640-654. doi:10.1056/NEJMoa2116133
Langenhorst JB, Dorlo TPC, van Maarseveen EM, et al. Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Clin Pharmacokinet. 2019;58(5):627-637. doi:10.1007/s40262-018-0715-9
Fabrizio VA, Boelens JJ, Mauguen A, et al. Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy [published correction appears in Blood Adv. 2023 Jun 27;7(12):2924]. Blood Adv. 2022;6(7):1961-1968. doi:10.1182/bloodadvances.2021006418
Dekker L, Calkoen FG, Jiang Y, et al. Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia. Blood Adv. 2022;6(7):1969-1976. doi:10.1182/bloodadvances.2021006700
Turtle CJ, Hanafi LA, Berger C, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621
Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126(6):2123-2138. doi:10.1172/JCI85309
Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129(25):3322-3331. doi:10.1182/blood-2017-02-769208
Shah NN, Lee DW, Yates B, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. 2021;39(15):1650-1659. doi:10.1200/JCO.20.02262
Amini L, Silbert SK, Maude SL, et al. Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion. Nat Rev Clin Oncol. 2022;19(5):342-355. doi:10.1038/s41571-022-00607-3
Hirayama AV, Gauthier J, Hay KA, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876-1887. doi:10.1182/blood-2018-11-887067
Scordo M, Flynn JR, Gonen M, et al. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma. Blood Adv. 2023;7(18):5579-5585. doi:10.1182/bloodadvances.2023010302
